Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Substitution with Different Strengths to Be Permitted
January 11, 2010
- Chuikyo to Modify Reform Proposal It OK'd on Dec. 22
January 11, 2010
- Measures to Promote Use of Generics to Save \19 Bil. in FY2010
January 11, 2010
- 5% Interest to Be Added to Refunds
January 11, 2010
- Teva-Kowa to Make Taisho Pharm. Its Own Subsidiary
January 11, 2010
- Change in Gov't Helped Drug Pricing System Reform: Mr Nagano
January 11, 2010
- Majority of Pharmacists Explain about Generics Only If Asked by Patients
January 11, 2010
- A Path Opns to Full-Scale Pricing System Reform: Mr Kinoshita
January 11, 2010
- Kyowa Kirin Licenses AD treatment from Immunas
January 11, 2010
- Virtual NHI Price Cut Rate in April to Be 6.5%
January 11, 2010
- Sanofi-aventis Enrolls 214 Patients in PIII Study of BSI-201
January 11, 2010
- Nippon Kayaku to Enter Market for Anticancer Biosimilars
January 11, 2010
- JSOM Welcomes Continued Insurance Coverage of Kampo Medicines
January 11, 2010
- Switchover from Tamoxifen to Aromasin Effective: Pfizer
January 11, 2010
- Januvia Ranked No. 1 in Both HP, GP Markets: Rep Track Survey
January 11, 2010
- New-Type Flu Vaccines from GSK, Novartis Recommended for Approval
January 11, 2010
- Increased Dose of Fulvestrant Reduces Risk of Breast Cancer Progression: AZ
January 11, 2010
- R&D Investment in Pharma Industry Up 3.3% in FY2008
January 11, 2010
- Solvay Applies for Pancreatic Enzyme Replacement Therapy
January 11, 2010
- 6 Medical Devices Recommended for Approval
January 11, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…